Validation of the breast cancer surveillance consortium model of breast cancer risk

Jeffrey A. Tice, Michael C.S. Bissell, Diana L Miglioretti, Charlotte C. Gard, Garth H. Rauscher, Firas M. Dabbous, Karla Kerlikowske

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: In order to use a breast cancer prediction model in clinical practice to guide screening and prevention, it must be well calibrated and validated in samples independent from the one used for development. We assessed the accuracy of the breast cancer surveillance consortium (BCSC) model in a racially diverse population followed for up to 10 years. Methods: The BCSC model combines breast density with other risk factors to estimate a woman’s 5- and 10-year risk of invasive breast cancer. We validated the model in an independent cohort of 252,997 women in the Chicago area. We evaluated calibration using the ratio of expected to observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC). Results: In an independent cohort of 252,997 women (median age 50 years, 26% non-Hispanic Black), the BCSC model was well calibrated (E/O = 0.94, 95% confidence interval [CI] 0.90–0.98), but underestimated the incidence of invasive breast cancer in younger women and in women with low mammographic density. The AUROC was 0.633, similar to that observed in prior validation studies. Conclusions: The BCSC model is a well-validated risk assessment tool for breast cancer that may be particularly useful when assessing the utility of supplemental screening in women with dense breasts.

Original languageEnglish (US)
JournalBreast Cancer Research and Treatment
DOIs
StatePublished - Jan 1 2019

Fingerprint

Breast Neoplasms
ROC Curve
Validation Studies
Calibration
Breast
Confidence Intervals
Incidence
Population

Keywords

  • Breast cancer surveillance consortium
  • Breast density
  • Breast neoplasms
  • Predictive value of tests
  • Risk assessment
  • ROC curve

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Validation of the breast cancer surveillance consortium model of breast cancer risk. / Tice, Jeffrey A.; Bissell, Michael C.S.; Miglioretti, Diana L; Gard, Charlotte C.; Rauscher, Garth H.; Dabbous, Firas M.; Kerlikowske, Karla.

In: Breast Cancer Research and Treatment, 01.01.2019.

Research output: Contribution to journalArticle

Tice, Jeffrey A. ; Bissell, Michael C.S. ; Miglioretti, Diana L ; Gard, Charlotte C. ; Rauscher, Garth H. ; Dabbous, Firas M. ; Kerlikowske, Karla. / Validation of the breast cancer surveillance consortium model of breast cancer risk. In: Breast Cancer Research and Treatment. 2019.
@article{0bbd80b2def84173a9dfe3ec329bd681,
title = "Validation of the breast cancer surveillance consortium model of breast cancer risk",
abstract = "Purpose: In order to use a breast cancer prediction model in clinical practice to guide screening and prevention, it must be well calibrated and validated in samples independent from the one used for development. We assessed the accuracy of the breast cancer surveillance consortium (BCSC) model in a racially diverse population followed for up to 10 years. Methods: The BCSC model combines breast density with other risk factors to estimate a woman’s 5- and 10-year risk of invasive breast cancer. We validated the model in an independent cohort of 252,997 women in the Chicago area. We evaluated calibration using the ratio of expected to observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC). Results: In an independent cohort of 252,997 women (median age 50 years, 26{\%} non-Hispanic Black), the BCSC model was well calibrated (E/O = 0.94, 95{\%} confidence interval [CI] 0.90–0.98), but underestimated the incidence of invasive breast cancer in younger women and in women with low mammographic density. The AUROC was 0.633, similar to that observed in prior validation studies. Conclusions: The BCSC model is a well-validated risk assessment tool for breast cancer that may be particularly useful when assessing the utility of supplemental screening in women with dense breasts.",
keywords = "Breast cancer surveillance consortium, Breast density, Breast neoplasms, Predictive value of tests, Risk assessment, ROC curve",
author = "Tice, {Jeffrey A.} and Bissell, {Michael C.S.} and Miglioretti, {Diana L} and Gard, {Charlotte C.} and Rauscher, {Garth H.} and Dabbous, {Firas M.} and Karla Kerlikowske",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10549-019-05167-2",
language = "English (US)",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Validation of the breast cancer surveillance consortium model of breast cancer risk

AU - Tice, Jeffrey A.

AU - Bissell, Michael C.S.

AU - Miglioretti, Diana L

AU - Gard, Charlotte C.

AU - Rauscher, Garth H.

AU - Dabbous, Firas M.

AU - Kerlikowske, Karla

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: In order to use a breast cancer prediction model in clinical practice to guide screening and prevention, it must be well calibrated and validated in samples independent from the one used for development. We assessed the accuracy of the breast cancer surveillance consortium (BCSC) model in a racially diverse population followed for up to 10 years. Methods: The BCSC model combines breast density with other risk factors to estimate a woman’s 5- and 10-year risk of invasive breast cancer. We validated the model in an independent cohort of 252,997 women in the Chicago area. We evaluated calibration using the ratio of expected to observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC). Results: In an independent cohort of 252,997 women (median age 50 years, 26% non-Hispanic Black), the BCSC model was well calibrated (E/O = 0.94, 95% confidence interval [CI] 0.90–0.98), but underestimated the incidence of invasive breast cancer in younger women and in women with low mammographic density. The AUROC was 0.633, similar to that observed in prior validation studies. Conclusions: The BCSC model is a well-validated risk assessment tool for breast cancer that may be particularly useful when assessing the utility of supplemental screening in women with dense breasts.

AB - Purpose: In order to use a breast cancer prediction model in clinical practice to guide screening and prevention, it must be well calibrated and validated in samples independent from the one used for development. We assessed the accuracy of the breast cancer surveillance consortium (BCSC) model in a racially diverse population followed for up to 10 years. Methods: The BCSC model combines breast density with other risk factors to estimate a woman’s 5- and 10-year risk of invasive breast cancer. We validated the model in an independent cohort of 252,997 women in the Chicago area. We evaluated calibration using the ratio of expected to observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC). Results: In an independent cohort of 252,997 women (median age 50 years, 26% non-Hispanic Black), the BCSC model was well calibrated (E/O = 0.94, 95% confidence interval [CI] 0.90–0.98), but underestimated the incidence of invasive breast cancer in younger women and in women with low mammographic density. The AUROC was 0.633, similar to that observed in prior validation studies. Conclusions: The BCSC model is a well-validated risk assessment tool for breast cancer that may be particularly useful when assessing the utility of supplemental screening in women with dense breasts.

KW - Breast cancer surveillance consortium

KW - Breast density

KW - Breast neoplasms

KW - Predictive value of tests

KW - Risk assessment

KW - ROC curve

UR - http://www.scopus.com/inward/record.url?scp=85061967790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061967790&partnerID=8YFLogxK

U2 - 10.1007/s10549-019-05167-2

DO - 10.1007/s10549-019-05167-2

M3 - Article

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -